Adicet Bio, Inc.

ACET · NASDAQ

Adicet is trying to turn prula-cel from a promising autoimmune CAR-T idea into a pivotal-trial story before its disclosed runway reaches the second half of 2027.

Follow Add to Watchlist Ask Question

NASDAQ ACET Coverage Bootstrap Biotechnology Cell Therapy CAR-T

Latest ReportMay 13, 2026Adicet Bio: the lupus CAR-T readout racing a 2027 cash runwayView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.